Breakfast Technical Briefing on Biotech Stocks -- Dynavax Technologies, Keryx Biopharma, Moleculin Biotech, and ZIOPHARM Oncology

Thursday, October 12, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, October 12, 2017 /PRNewswire/ --

If you want a Stock Review on DVAX, KERX, MBRX, or ZIOP then come over

to and sign up for your free customized report. Pre-market today, redirects investors' attention to the Biotechnology industry, which consists of companies engaged in the research and development
of new drugs, medical devices, and procedures. Equities under review this morning are: Dynavax Technologies Corp. (NASDAQ: DVAX), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Moleculin Biotech Inc. (NASDAQ: MBRX), and ZIOPHARM Oncology Inc. (NASDAQ: ZIOP). Daily Stock Tracker published free research reports on these stocks today at:

Dynavax Technologies 

Berkeley, California headquartered Dynavax Technologies Corp.'s shares declined 0.43%, closing Wednesday's trading session at $23.05. The stock recorded a trading volume of 1.34 million shares. The Company's shares have advanced 14.11% in the last month, 151.91% over the previous three months, and 483.54% since the start of this year. The stock is trading 20.60% above its 50-day moving average and 145.68% above its 200-day moving average. Additionally, shares of Dynavax Technologies, which focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation, have a Relative Strength Index (RSI) of 66.72.

On September 25th, 2017, research firm RBC Capital Markets reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $26 a share to $28 a share. See our free and comprehensive research report on DVAX at:

Keryx Biopharmaceuticals 

On Wednesday, shares in Boston, Massachusetts headquartered Keryx Biopharmaceuticals Inc. recorded a trading volume of 1.28 million shares, which was above their three months average volume of 1.17 million shares. The stock dropped 3.91%, ending the day at $7.37. The Company's shares have advanced 1.80% in the past month and 25.77% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 4.21% and 16.23%, respectively. Furthermore, shares of Keryx Biopharma, which focuses on providing medicines for patients with renal disease in the US, have an RSI of 53.16.

On September 13th, 2017, Keryx Biopharma (KERX) announced the appointment of Mark J. Enyedy as an independent member of its Board of Directors. Mr. Enyedy brings extensive biopharmaceutical leadership experience to the Company. John Butler, Chairman of KERX's Board and President and CEO of Akebia Therapeutics, Inc., has resigned from the former's Board. Current KERX's Board member Michael Rogers has been appointed as Chairman of the Board. These changes are effective immediately. KERX free research report is just a click away at:

Moleculin Biotech 

Houston, Texas headquartered Moleculin Biotech Inc.'s stock finished the day 2.13% lower at $2.30 with a total trading volume of 634,923 shares. The Company's shares have advanced 42.86% in the previous three months and 0.88% on an YTD basis. The stock is trading above its 200-day moving average by 37.73%. Additionally, shares of Moleculin Biotech, which focuses on the development of anti-cancer drug candidates, have an RSI of 39.73.

On October 03rd, 2017, Moleculin Biotech announced that it has entered into an agreement to conduct its clinical trial to study Annamycin for the treatment of acute myeloid leukemia with the first of several hospitals desiring to be treatment centers. Walter Klemp, the Company's Chairman and CEO, commented: "We have identified 14 treatment sites that meet our criteria and have expressed an interest in participating, so there will be much more of this to come." Sign up for your complimentary report on MBRX at:

ZIOPHARM Oncology 

Shares in Boston, Massachusetts headquartered ZIOPHARM Oncology Inc. ended yesterday's session 3.21% lower at $5.72. The stock recorded a trading volume of 1.79 million shares, which was above its three months average volume of 1.03 million shares. The Company's shares have advanced 6.92% since the start of this year. The stock is trading 4.10% below its 50-day moving average. Moreover, shares of ZIOPHARM, which focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology, have an RSI of 39.95.

On September 28th, 2017, ZIOPHARM announced the appointment of David Mauney, M.D. as Executive Vice President and Chief Business Officer, effective that day. With 20 years of experience in the raising, management, and disposition of almost $900 million in life science venture capital, Dr. Mauney will lead the Company's corporate development and investor strategy functions, reporting directly to Laurence Cooper, M.D., Ph.D., CEO. Register for free on and download the latest research report on ZIOP at:

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

DST has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)-331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store